Trial
NCT03646461
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of California, San Diego
Collaborators
Pharmacyclics LLC.
Condition
Head and Neck Cancer
Intervention
Ibrutinib 560mg PO daily (Imbruvica)
Why stopped
Lack of scientific process of cancer-related clinical intervention
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-22